Skip to main content

Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non–small-cell lung cancer (aNSCLC) in the United States.

Abstract

9117
Background: Multiple biomarker testing strategies exist as the treatments of aNSCLC rapidly evolve. While upfront NGS is considered optimal, this practice has not been universally adopted. Surprisingly, the impact of NGS vs non-NGS approaches on OS is unclear, with the largest study to date demonstrating lack of benefit. We aim to identify the genomic testing strategy associated with the most optimal OS in aNSCLC using data from a large, contemporary electronic health record (EHR) database. Methods: This retrospective study used Flatiron EHR data. Patients diagnosed with aNSCLC between 11 Apr 2019 and 31 Dec 2021 who received systemic therapy were identified and followed from the date of diagnosis to 31 May 2022 or death. Testing methods reported within the patient’s chart were extracted. Methods assessed included NGS (defined as any test type with ‘NGS’ as test name) and non-NGS (defined as PCR, FISH, IHC, and other sequencing methods not containing ‘NGS’). Upfront testing was defined as tests received on or prior to the date of initiation of first-line (1L) therapy. Kaplan-Meier analyses were used to estimate and compare real-world overall survival (rwOS) by testing strategies. Among those with actionable genetic mutations, we also explored rwOS by timing of targeted therapy (TT) initiation. Results: Of a total 13,139 patients, mean age was 69, 49% female, 64% white, 33% Medicare insured, and 88% treated in community setting only. Median follow up time was 9 months. The percentage of patients with upfront NGS increased from 29% in 2019 to 66% in 2022. Median OS (mOS) was longest in patients with upfront NGS compared to those with upfront non-NGS genomic tests (p < 0.05), those with NGS after 1L (p < 0.05), and those with no NGS test ever (p < 0.05) (see table). 19% of patients with upfront NGS vs. 15% of those with upfront non-NGS received TT in 1L; 23% of patients with NGS vs. 19% of those with upfront non-NGS received TT at any line of therapy. In patients with actionable genetic mutations, mOS decreased with later initiation of TT; mOS was not reached (NR) (34.6 – NR) in patients who initiated TT in 1L, 34.7 (29.1 – NR) months in those with 2L TT, and 24.3 (20.3 – 30.1) months in those who initiated TT in 3L. Conclusions: This is the first and largest study to demonstrate that upfront NGS testing leads to better OS when compared to upfront non-NGS genomic testing, later NGS, or no-NGS in aNSCLC. In line with these results, we also found an OS benefit associated with earlier TT initiation. These results highlight the significant impact of upfront NGS testing and underscore for the need for both education and wider accessibility of NGS testing.
 Upfront NGS testing
(n = 6,210)
Upfront non-NGS genomic testing (n = 2,697)NGS testing after 1L initiation
(n = 2,824)
No NGS tested ever
(n = 2,152)
Median OS (CI) in months20.9
(19.8-21.9)
17.5
(16.1-19.2)
18.2
(16.6-19.4)
16.9
(15.3-18.6)

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

Journal of Clinical Oncology
Pages: 9117

History

Published online: May 31, 2023
Published in print: June 01, 2023

Permissions

Request permissions for this article.

Authors

Affiliations

Benjamin Philip Levy
John Hopkins Sidney Kimmel Cancer Center, Washington, DC
Danny Nguyen
City of Hope, Duarte, CA
Yu-Hsuan Shih
Novartis Services, Inc, East Hanover, NJ
Magdaliz Gorritz
Beilei Cai
Novartis Services, Inc, East Hanover, NJ
Nydia Caro
Novartis Services, Inc, East Hanover, NJ
Marie Yasuda
Yifan Gu
Chi-Chang Chen
Vincent Pretre
Novartis Services, Inc, East Hanover, NJ
Teddy Rassem Saliba
Novartis Services, Inc, East Hanover, NJ
John Hopkins Sidney Kimmel Cancer Center, Washington, DC; City of Hope, Duarte, CA; Novartis Services, Inc, East Hanover, NJ; IQVIA, Inc, Wayne, PA

Notes

Funding Information

Novartis, Incpharma

Metrics & Citations

Metrics

Altmetric

Citations

Article Citation

Download Citation

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Benjamin Philip Levy, Danny Nguyen, Yu-Hsuan Shih, Magdaliz Gorritz, Beilei Cai, Nydia Caro, Marie Yasuda, Yifan Gu, Chi-Chang Chen, Vincent Pretre, Teddy Rassem Saliba
Journal of Clinical Oncology 2023 41:16_suppl, 9117-9117

View Options

View options

PDF

View PDF

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login

Purchase Options

Purchase this article to get full access to it.

Purchase this Article

Subscribe

Subscribe to this Journal
Renew Your Subscription
Become a Member

Media

Figures

Other

Tables

Share

Share

Share article link

Share